NuCana (NCNA) announced on Tuesday the appointment of Theresa Bruce as chief operating officer, effective January 1, 2026.
Bruce previously served as chief operating officer at Nexus Oncology and has held senior leadership roles at both clinical research organizations and biotechnology companies, including senior vice president of clinical operations at Chiltern and Veristat. Most recently, Bruce served as Senior Vice President of Clinical Operations at NuCana. Before joining NuCana, she also worked as an independent consultant to U.S.-based biotechnology companies.
NCNA -1.24% premarket to $3.654.
Source: Press Release
